In this issue:
- Recurrent alcohol associated hepatitis
- Tirzepatide for MASH with liver fibrosis
- Predictors of long-term HBsAg seroclearance after entecavir cessation
- HBV RNA decline predicts HCC risk
- Treatment response and clinical event-free survival in AIH
- Liver stiffness in alcohol related liver disease
- Infliximab for AIH
- Hepatitis C testing in hospital inpatients
- Alcohol and increased risk for progressive liver disease
- Baseline viral load and on-treatment HCC risk in CHB
Please login below to download this issue (PDF)